Clinical Trial Update: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating adebrelimab in combination with dalpiciclib and standard endocrine therapy for HR+/HER2- breast cancer; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: Harbin Medical University | Conditions: Breast Cancer, HR+/HER2- Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING